landiolol has been researched along with Heart Failure in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Ebina, T; Hanajima, Y; Hibi, K; Horii, M; Iwahashi, N; Kimura, K; Kimura, Y; Kirigaya, J; Kosuge, M; Matsuzawa, Y; Minamimoto, Y; Okada, K; Takahashi, H; Tamura, K | 1 |
| Colombo, C; Ditali, V; Garatti, L; Morici, N; Oliva, F; Sacco, A; Villanova, L | 1 |
| Abe, T; Hagiwara, N; Jujo, K; Kametani, M; Minami, Y; Shiga, T; Shirotani, S; Suzuki, A | 1 |
| Chalkias, A; O'Donnell, EP | 1 |
| Dabrowski, W; Jaroszynski, A; Piasek, E; Schlegel, TT; Siwicka-Gieroba, D | 1 |
| Akitsu, K; Fujino, T; Ikeda, T; Kinoshita, T; Koike, H; Shinohara, M; Suzuki, T; Wada, R; Yano, K | 1 |
| Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H | 1 |
| Syed, YY | 1 |
| Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T | 1 |
| Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A | 1 |
| Doi, M; Kobayashi, S; Matsuzaki, M; Murakami, W; Myoren, T; Nao, T; Okuda, S; Tateishi, H; Wada, Y; Yano, M | 1 |
| Matsushita, M; Saitoh, T; Yamashita, T | 1 |
| Abe, M; Akao, M; Hamatani, Y; Iguchi, M; Ishii, M; Masunaga, N; Nakatani, R; Ogawa, H; Takagi, D; Unoki, T; Usui, T; Yamashita, Y | 1 |
| Amiya, E; Endo, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Nitta, D | 1 |
| Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J | 1 |
| Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M | 1 |
| Yasumura, Y | 1 |
2 review(s) available for landiolol and Heart Failure
| Article | Year |
|---|---|
Mechanisms of landiolol-mediated positive inotropy in critical care settings.
Topics: Adrenergic beta-Antagonists; Animals; Critical Care; Critical Illness; Heart Failure; Heart Rate; Humans; Urea | 2023 |
Landiolol: A Review in Tachyarrhythmias.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Approval; Heart Failure; Heart Rate; Humans; Japan; Morpholines; Tachycardia; Tachycardia, Supraventricular; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2018 |
1 trial(s) available for landiolol and Heart Failure
| Article | Year |
|---|---|
Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Female; Heart Failure; Heart Rate; Humans; Infant; Infusions, Intravenous; Male; Morpholines; Research Design; Tachycardia; Urea | 2017 |
14 other study(ies) available for landiolol and Heart Failure
| Article | Year |
|---|---|
Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment.
Topics: Atrial Fibrillation; Heart Failure; Hospital Mortality; Humans; Morpholines; Prognosis; Prospective Studies; Stroke Volume; Urea; Ventricular Function, Left | 2022 |
Effect of landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series.
Topics: Heart Failure; Humans; Morpholines; Tachycardia; Urea | 2022 |
Prognostic Impact of Landiolol in Patients with Acute Heart Failure and Atrial Fibrillation with Rapid Ventricular Rates: A Pilot Observational Study.
Topics: Atrial Fibrillation; Heart Failure; Humans; Morpholines; Prognosis | 2022 |
Successful Combination of Landiolol and Levosimendan in Patients with Decompensated Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Morpholines; Simendan; Tachycardia; Urea | 2020 |
Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Digoxin; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Severity of Illness Index; Stroke Volume; Tachycardia; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2020 |
Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction.
Topics: Administration, Cutaneous; Administration, Intravenous; Adrenergic beta-Antagonists; Adult; Atrial Fibrillation; Bisoprolol; Female; Gastrointestinal Diseases; Heart Failure; Humans; Morpholines; Thyroid Crisis; Treatment Outcome; Urea | 2017 |
A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Heart Failure; Heart Rate; Humans; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Urea | 2019 |
Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Morpholines; Tachycardia, Supraventricular; Time Factors; Treatment Outcome; Urea | 2014 |
A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Female; Heart Failure; Heart Rate; Humans; Male; Morpholines; Urea | 2014 |
Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Atrial Fibrillation; Atrial Flutter; Female; Heart Failure; Humans; Japan; Male; Morpholines; Prospective Studies; Research Design; Urea | 2015 |
Thyroid Storm with Heart Failure Treated with a Short-acting Beta-adrenoreceptor Blocker, Landiolol Hydrochloride.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electric Countershock; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Morpholines; Tachycardia; Thyroid Crisis; Thyroidectomy; Treatment Outcome; Urea | 2015 |
An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension.
Topics: Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Biological Availability; Cardiomyopathy, Dilated; Electrocardiography; Heart Failure; Humans; Hypotension; Intra-Aortic Balloon Pumping; Male; Mitral Valve Insufficiency; Morpholines; Severity of Illness Index; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Young Adult | 2015 |
Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Japan; Male; Middle Aged; Milrinone; Morpholines; Prospective Studies; Pulmonary Wedge Pressure; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Combination of β-blocker and milrinone for acute heart failure.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Male; Milrinone; Morpholines; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |